PAM Theragnostics Partners with FyoniBio to Establish a Production Process for PAM’s Lead Compound to prevent Alzheimer’s Disease
FyoniBio has entered a collaboration with PAM Theragnostics to establish a production process for PAM Theragnostics’ lead compound, peptidylglycine alpha-amidating monooxygenase — PAM — a complex glycoprotein being developed for the prevention of Alzheimer’s disease. With its CHOnamite® cell line development platform and long-standing expertise in glycobiology, FyoniBio will support the development of a robust and scalable process for this promising therapeutic candidate.